Summary
Circulating immune complexes were measured using a modified C1q binding assay in 100 preoperative patients with colorectal cancer and in 52 patients with benign polyps. Sixty-one per cent of the patients with cancer and 49 per cent of the patients with benign polyps had elevated levels, as did 92 per cent of those with malignant polyps. There was no relation to a, the stage of the disease, with 10 out of 13 Dukes' A tumours (77 per cent) having increased levels; b, the degree of differentiation of the cancers; c, the tumour mass. However, cancers on the right side of the colon had significantly higher levels than rectal cancers.
Contributor Information
K D Vellacott, Department of Surgery and Cancer Research Campaign Laboratories, University of Nottingham.
R W Baldwin, Department of Surgery and Cancer Research Campaign Laboratories, University of Nottingham.
T W Balfour, Department of Surgery and Cancer Research Campaign Laboratories, University of Nottingham.
J D Hardcastle, Department of Surgery and Cancer Research Campaign Laboratories, University of Nottingham.
References
- 1. Price M R and Baldwin R W: Shedding of tumour cell surface antigens. Cell Surface Rev. 1977; 3: 424–71. [Google Scholar]
- 2. Baldwin R W and Robins R A: Circulating immune complexes in cancer. In: Sell S (ed.): Cancer Markers: Development and Diagnostic Significance. Clifton, N. J.: Humana Press, 1980; 19: 507–31. [Google Scholar]
- 3. Hoffken K, Meredith I D, Robins R A et al. : Circulating immune complexes in patients with breast cancer. Br. Med. J. 1977; 2: 218–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Lowe J, Segal-Eiras A, Iles P B et al. Circulating immune complexes in patients with lung cancer. Thorax 1981; 36: 56–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Segal-Eiras A, Robins R A, Baldwin R W et al. : Circulating immune complexes in patients with bone tumours. Int. J. Cancer 1980; 25: 735–9. [DOI] [PubMed] [Google Scholar]
- 6. Rossen R D, Reisberg M A, Hersh E M et al. : The C1q binding test for solubid immune complexes: clinical correlations obtained in patients with cancer. J. Natl. Cancer Inst. 1977; 58: 1205–15. [DOI] [PubMed] [Google Scholar]
- 7. Doyle P J, Robins R A, Webb P G et al. : A modified C1q binding assay in breast cancer. Clin. Exp. Immunol. 1981. (In the press.)
- 8. Heusser C, Boesman M, Nordin J H et al. : Effect of chemical and enzymatic radioiodination on in vitro human C1q activity. J. Immunol. 1973; 10: 820–8. [PubMed] [Google Scholar]
- 9. Cooper M J, Mackie C R, Skinner D B et al. : A reappraisal of the value of carcinoembryonic antigen in the management of patients with various neoplasms. Br. J. Surg. 1979; 66: 120–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Martin E W, Kibbey W E, Divecchia A et al. : Carcinoembryonic antigen. Clinical and historical aspects. Cancer 1976; 37: 62–81. [DOI] [PubMed] [Google Scholar]
- 11. Livingstone A S, Hampson L G, Shuster J et al. : Carcinoembryonic antigen in the diagnosis and management of colorectal carcinoma: current status. Arch. Surg. 1974; 109: 259–64. [DOI] [PubMed] [Google Scholar]
- 12. Kemler B J and Alpert E: Inflammatory bowel disease associated circulating immune complexes. Gut 1980; 21: 195–201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Price M R, Laughlin P J, Robins R A et al. : Tumour markers with unknown functions in gynaecological neoplasm. Arch. Gynecol. 1980; 229: 325–31. [DOI] [PubMed] [Google Scholar]